Analyst Evercore ISI set a $255 price target for ResMed [RMD:NYSE], indicating an 11.68% potential upside from its $228.33 stock price.
Despite the positive analyst outlook, ResMed executives, including CEO Michael Farrell, have sold over $1.5 million in shares through pre-arranged trading plans.
Investors await ResMed's Q3 2026 earnings report on April 30, 2026, for insights into the company's financial health, given its current $32.67 billion market capitalization and recent stock fluctuations.
ResMed [RMD:NYSE] is a leading medical equipment company that specializes in developing and selling innovative devices for treating sleep-disordered breathing, including sleep apnea. This healthcare stock also offers advanced cloud-connected medical devices designed to help manage patients with chronic diseases. The company operates within a highly competitive market for respiratory care devices.
On April 13, 2026, a prominent analyst from Evercore ISI adjusted the price target for ResMed (RMD) stock to $255. At the time of the rating, the stock's price was $228.33. This updated RMD stock forecast suggests a significant potential upside of approximately 11.68% from the price at which the rating was published.
This positive analyst rating adjustment coincides with notable ResMed insider selling activity. As reported by defenseworld.net, CEO Michael Farrell divested 4,991 shares of RMD stock for over $1.1 million. Similarly, Director Peter Farrell sold 2,000 shares, generating $450 thousand. These insider stock sales were executed under pre-arranged trading plans, which are predetermined schedules for selling stocks set up in advance.
Following these developments, RMD shares opened at $229.03 on a recent Friday. The stock's price has experienced significant fluctuation over the past year, reaching a 12-month high of $293.81 and a low of $202.00. Currently, the medical equipment company boasts a robust market capitalization of $32.67 billion, representing the total value of all its outstanding shares.
Investors are keenly anticipating ResMed's next financial update. As reported by GlobeNewswire, ResMed is scheduled to release its third-quarter results for fiscal year 2026 on April 30, 2026. This crucial earnings report will offer new insights into the company's financial health and overall operational performance.
